share_log

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

Benzinga Real-time News ·  May 13, 2022 10:43

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

Switzerland Approves Moderna's COVID-19 Shot For Kids 6-11

The Swiss drug regulatory authority has approvedModerna Inc's(NASDAQ:MRNA) COVID-19 vaccine for children ages 6-11.

The approval is for the vaccine's two-dose series of 50 micrograms per dose, Moderna added.

Shares were up 6.72% at $138.92 Friday.

Neurocrine's Huntington's Candidate Secures FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation toNeurocrine Biosciences Inc's(NASDAQ:NBIX) valbenazine for Huntington's disease (HD).

The treatment of chorea associated with...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment